Drug Resistance Among PrEP Recipients — How Big a Concern?

Data from the iPrEx trial showed infrequent low-level resistance in those who became HIV-infected while taking pre-exposure prophylaxis.

Uptake of pre-exposure prophylaxis (PrEP) among individuals at risk for acquiring HIV infection has been slow despite clinical trial data showing efficacy in different populations. Reasons for this are multiple and complex, but one issue of concern is selection for antiretroviral-resistant virus in PrEP users who become HIV-infected. The Chemoprophylaxis for HIV Prevention in Men (iPrEx) study is a phase III clinical trial designed to determine whether daily tenofovir/FTC can safely and effectively prevent HIV infection among men (and transgendered women) who have sex with men.

In this trial, 48 of the 1226 persons randomized to receive tenofovir/FTC acquired an incident HIV infection. Based on clinical drug-resistance assays, none of these …

Reviewing Author

Charles B. Hicks, MD

Disclosures

Consultant / Advisory boardGilead Sciences; ViiV; Merck

RoyaltiesUpToDate, Inc.

Grant / Research supportNIH; Department of Health and Human Services

Charles B. Hicks, MD

Disclosures

Consultant / Advisory boardGilead Sciences; ViiV; Merck

RoyaltiesUpToDate, Inc.

Grant / Research supportNIH; Department of Health and Human Services

Drug Resistance Among PrEP Recipients — How Big a Concern?

Topics

Reviewing Author